A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

Castration Resistant ◽

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Cited By ~ 58

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase

A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4532 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4532-4532 ◽

Cited By ~ 4

Author(s):

E. S. Antonarakis ◽

E. I. Heath ◽

D. C. Smith ◽

D. E. Rathkopf ◽

A. L. Blackford ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Dose Levels

Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e16034 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16034-e16034

Author(s):

Luis Leon Mateos ◽

Laura Muinelo ◽

Begoña Perez-Valderrama ◽

Begoña Mellado ◽

María José Juan Fita ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Tumour Cell ◽

Phase Ii Study ◽

Castration Resistant ◽

Docetaxel Treatment ◽

Circulating Tumour Cell

A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5081 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5081-5081 ◽

Cited By ~ 1

Author(s):

Joyce M. van Dodewaard-de Jong ◽

Haiko Bloemendal ◽

John M. H. de Klerk ◽

Daniela E Oprea-Lager ◽

Otto S. Hoekstra ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy

The Prostate ◽

10.1002/pros.21485 ◽

2011 ◽

Vol 72 (8) ◽

pp. 834-845 ◽

Cited By ~ 32

Author(s):

Masanori Noguchi ◽

Fukuko Moriya ◽

Shigetaka Suekane ◽

Kei Matsuoka ◽

Gaku Arai ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Peptide Vaccination ◽

Castration Resistant

7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71382-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 407 ◽

Cited By ~ 2

Author(s):

K.N. Chi ◽

S.J. Hotte ◽

E. Yu ◽

D. Tu ◽

B. Eigl ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients

Investigational New Drugs ◽

10.1007/s10637-016-0385-0 ◽

2016 ◽

Vol 34 (6) ◽

pp. 760-770 ◽

Cited By ~ 17

Author(s):

Teresa Di Desidero ◽

Lisa Derosa ◽

Luca Galli ◽

Paola Orlandi ◽

Andrea Fontana ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Prospective Phase ◽

Metronomic Vinorelbine

Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)

Annals of Oncology ◽

10.1093/annonc/mdw372.37 ◽

2016 ◽

Vol 27 ◽

pp. vi255 ◽

Cited By ~ 1

Author(s):

U. Anido ◽

M.J. Juan Fita ◽

L. Munielo-Romay ◽

B. Pérez-Valderrama ◽

B. Mellado ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Tumour Cell ◽

Phase Ii Study ◽

Castration Resistant ◽

Circulating Tumour Cell

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000131 ◽

2014 ◽

Vol 25 (9) ◽

pp. 1081-1088 ◽

Cited By ~ 8

Author(s):

Jean-Pierre Droz ◽

Jaques Medioni ◽

Christine Chevreau ◽

Helene De Mont-Serrat ◽

Michael Merger ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽